Kairos Pharma Expands Oncology Pipeline with Proposed Acquisition of Phase 1-Ready c-MET Inhibitor
Kairos Pharma's mid-year update reveals plans to acquire CL-741, a Phase 1-ready oral c-MET inhibitor, expand clinical trials for ENV-105, and secure over $8 million in non-dilutive funding, signaling significant pipeline growth and potential advancements in cancer treatment.
Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 update highlighting plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics. CL-741 targets EGFR-mutated lung cancer and other cancers, and the company stated it would complement its existing portfolio, which includes ENV-105, KROS-201, KROS-102 and ENV-205.
This strategic move underscores Kairos Pharma's commitment to addressing drug resistance and immune suppression in cancer, a focus that has driven its research and development. The company expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings and pursue pharmaceutical collaborations. These milestones highlight the company's progress in tackling significant unmet medical needs.
Kairos Pharma also noted it has secured more than $8 million in non-dilutive funding to support development of its preclinical and clinical programs. This funding provides a financial cushion without diluting shareholder value, which is particularly important for a company in the capital-intensive biotech sector. The non-dilutive nature of this funding could enhance investor confidence as the company advances its pipeline.
The company's lead candidate, ENV-105, is an antibody targeting CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 is currently in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer. The expansion of the pipeline with CL-741 could provide additional avenues for growth and diversification, reducing reliance on a single drug candidate.
The news matters because it signals potential progress in oncology treatments, particularly for patients with EGFR-mutated lung cancer and other cancers where c-MET inhibition may be effective. For investors, the update provides insight into Kairos Pharma's strategic direction and financial health. The company's ability to secure non-dilutive funding and pursue pipeline expansion suggests a proactive approach to growth, though investors should note that ENV-105 has not yet been approved by the U.S. Food and Drug Administration or any other comparable foreign regulator.
For more details, the full press release is available at https://ibn.fm/WuBOf. Latest news and updates relating to KAPA can be found in the company's newsroom at https://ibn.fm/KAPA.